CA
ELVN icon

Clearstead Advisors’s Enliven Therapeutics ELVN Stock Holding History

Clearstead Advisors’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51 Buy
+1
New +$42 ﹤0.01% 3477
2025
Q4 		– Sell
-5
Closed -$103 – 2897
2025
Q3 		$103 Buy
+5
New +$101 ﹤0.01% 2932

Other funds holding ELVN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Clearstead Advisors's ELVN Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 1 share worth $51. The stake represents ﹤0.01% of the portfolio and ranks #3477 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in ELVN as recently as Q3 2025.

Clearstead Advisors first reported a position in ELVN in Q3 2025 and has held it in 2 quarters since. The position peaked at $103 in Q3 2025. 49 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Clearstead Advisors held 1 share of Enliven Therapeutics worth $51 as of Q2 2026.
  • Enliven Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Enliven Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3477 holding.
  • Clearstead Advisors first reported a position in Enliven Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Clearstead Advisors's Enliven Therapeutics position peaked at $103 in Q3 2025.
  • 49 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.